首页> 外文期刊>BMC Neurology >Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2 + and decreased levels of IL23R + CD4 + T - Lymphocytes in multiple sclerosis
【24h】

Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2 + and decreased levels of IL23R + CD4 + T - Lymphocytes in multiple sclerosis

机译:初步研究:肌内干扰素β-1a的治疗导致多发性硬化症中IL-12Rβ2+的水平升高和IL23R + CD4 + T淋巴细胞的水平降低

获取原文
           

摘要

Background There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis (MS) patients receiving interferon beta (IFN-β). Thus the objective of this study was to characterize changes in CD4+ T-lymphocyte expression in an unbiased manner following initiation of intramuscular (IM) IFN-β-1a treatment, and then to verify those findings using marker-specific assays. Methods Peripheral blood specimens were collected from twenty MS patients before and after treatment with intramuscular (IM) IFN-β-1a and were used for isolation of mononuclear cells (PBMCs). mRNA expression patterns of negatively-selected CD4+ T-cells from the PBMCs were analyzed using microarray gene expression technology. IL-12 and IL-23 receptor levels on PBMC-derived CD4+ T-cells were analyzed by flow cytometry. The phosphorylation status of Stat4 was measured by performing densitometry on western blots. Results Microarray analyses demonstrated that mRNA expression of the IL-12Rβ2 gene was uniformly up-regulated in response to IFN-β-1a treatment and was associated with an increased number of IL-12Rβ2+ CD4+ T-cells by flow cytometry in 4 of 6 patients. This finding was substantiated by demonstrating that Stat4 phosphorylation, a transcription factor for IL-12, was increased after treatment. Conversely, the number of IL-23R+ CD4+ T-cells was decreased following treatment. Conclusions The IL-12 receptor shares a common subunit, the IL-12Rβ2, with the IL-23 receptor. Both of these receptors have a probable role in regulating IL-17 and TH-17 cells, important mediators of inflammation in multiple sclerosis (MS). Thus, the changes in the numbers of CD4+ T-cells expressing these receptors in response to IFN-β-1a treatment may point to an important mechanism of action for this drug, but further large scale studies are needed to confirm these preliminary observations.
机译:背景技术缺乏可用于预测接受干扰素β(IFN-β)的多发性硬化症(MS)患者临床结果的生物标志物。因此,本研究的目的是在开始肌肉内(IM)IFN-β-1a治疗后以无偏见的方式表征CD4 + T淋巴细胞表达的变化,然后使用标记物特异性测定法验证这些发现。方法收集20例MS患者在肌注IFN-β-1a前后的外周血标本,用于分离单核细胞(PBMC)。使用微阵列基因表达技术分析了来自PBMCs的阴性选择的CD4 + T细胞的mRNA表达模式。通过流式细胞术分析了PBMC来源的CD4 + T细胞上的IL-12和IL-23受体水平。 Stat4的磷酸化状态通过在Western印迹上进行光密度测定来测量。结果芯片分析表明,IL-12Rβ2基因的mRNA表达在IFN-β-1a的作用下均匀上调,并与IL-12Rβ2 + CD4 的增加有关流式细胞术检测6例患者中的+ T细胞。通过证明Stat12磷酸化(IL-12的转录因子)在治疗后增加,证实了这一发现。相反,治疗后IL-23R + CD4 + T细胞数量减少。结论IL-12受体与IL-23受体共有一个亚基,即IL-12Rβ2。这两种受体在调节IL-17和TH-17细胞(多发性硬化症(MS)中炎症的重要介质)中可能发挥作用。因此,响应IFN-β-1a治疗,表达这些受体的CD4 + T细胞数量的变化可能表明该药物的重要作用机制,但进一步的大规模研究仍在进行中。需要确认这些初步观察结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号